Skip to main content

Table 2 Number of days with migraine headache per month and 50% reduction in this number

From: A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

  ITT population (n = 68) PP population (n = 62)
No. of days with migraine headache per month (mean ± SD)
Baseline phase 4.9 ± 2.6 5.1 ± 2.5
1st month 2.4 ± 3.1* 2.5 ± 3.2*
2nd month 1.9 ± 2.3* 2 ± 2.4*
3rd month 1.3 ± 1.5* 1.4 ± 1.6*
% of patients with ≥ 50% reduction in no. of days with migraine headache per month (% [CI 95%])
1st month 63.2% [51.8–74.7] 64.5% [52.6–76.4]
2nd month 70.6% [59.8–81.4] 71.0% [59.7–82.3]
3rd month 75% [64.7–85.3] 74.2% [63.3–85.1]
  1. *p < 0.0001 versus baseline phase
  2. CI confidence interval